Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pexastimogene devacirepvec + cemiplimab
- Development stage
- Phase 2
- Lead developer
- SillaJen
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Intratumoral
01
Overview
Combination immunotherapy consisting of **pexastimogene devacirepvec (Pexa-Vec)**, an engineered oncolytic vaccinia virus, and **cemiplimab** (a monoclonal antibody checkpoint inhibitor targeting programmed cell death protein 1 [PD-1]). Pexa-Vec selectively infects and lyses tumor cells, expressing granulocyte-macrophage colony-stimulating factor (GM-CSF) to induce systemic anti-tumor immune responses. Cemiplimab blocks PD-1-mediated immune suppression, restoring T-cell activity against tumors. In clinical studies, this combination has shown an acceptable safety profile, promising overall response rates, and evidence of durable responses in metastatic or unresectable renal cell carcinoma[5][7][9]. The main indications under investigation are metastatic renal cell carcinoma; the drug is being trialed in other solid tumors.
- Brand names
- Libtayo (cemiplimab)Pexa-Vec (pexastimogene devacirepvec)
- Other names
- pexastimogene devacirepvecJX-594JX594JX 594Pexa-VeccemiplimabREGN2810REGN-2810REGN 2810Libtayo
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)TK1 (Thymidine kinase 1)GM-CSF (Granulocyte-macrophage colony-stimulating factor)
Beyond the preview
Go deeper on pexastimogene devacirepvec + cemiplimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pexastimogene devacirepvec + cemiplimab.